Jung Won Shin
Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector.
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jung Won Shin
CrystalGenomics Eyes COVID-19 Trials As Hopes Rise For Ivaltinostat
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.
Korean CROs Narrow Gap But Seek Continued State Support
A trade institute's recent report emphasizes that government support is still needed although South Korean CRO industry has grown sharply in recent years and suggests ways to improve global competitiveness.
Celltrion Pledges Efforts on Coronavirus Antibody And Kit
Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.
Korea Moves To Stabilize Drug Supplies, Works With WHO On Coronavirus
South Korea moves to maintain stability of drug supply and demand amid the coronavirus pandemic, while the WHO participates in the country’s clinical epidemiology research that could potentially be used to revise and complement international guidance on COVID-19 disease.
Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Vaccine Development
Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.
Celltrion Accelerates Antibody, Kit Development As It Takes Coronavirus Initiative
Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.